Liraglutide (Saxenda, Victoza)

Liraglutide is a 31-amino-acid GLP-1 analog with a single Lys26 fatty-acid modification (palmitoyl C16). It binds the GLP-1 receptor with high affinity and produces the canonical incretin effects — insulin secretion in response to glucose, glucagon suppression, slowed gastric emptying, and central appetite suppression.^[1]

Two formulations exist: Victoza (1.2 mg or 1.8 mg daily) for type 2 diabetes, and Saxenda (3.0 mg daily) for obesity.

Liraglutide was the first long-acting GLP-1 receptor agonist designed for once-daily dosing, building on the lessons of exenatide (the earlier exendin-4-based agent) and the broader incretin field. It was approved in Europe in 2009 and by the FDA as Victoza for type 2 diabetes in 2010, then as Saxenda for chronic weight management in 2014. Liraglutide remains the molecular template from which semaglutide was developed.^[1]

Mechanistically, liraglutide is the older sibling of semaglutide — the same receptor, the same pathway. The clinical differences between the two are largely about dosing convenience, magnitude of weight loss, and the breadth of cardiovascular and renal outcomes data accumulated.^[2]

Liraglutide's 13-hour plasma half-life supports once-daily subcutaneous dosing. Its design uses a C16 fatty-acid linker for albumin binding — the same general strategy later refined in semaglutide with a longer C18 diacid for once-weekly dosing. Bioavailability after subcutaneous administration is approximately 55%.

The peer-reviewed literature on Liraglutide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

Both Victoza and Saxenda are administered as once-daily subcutaneous injections, with stepwise dose titration over four to five weeks to manage gastrointestinal side effects. Saxenda titrates from 0.6 mg up to 3.0 mg daily.

Liraglutide remains a clinically useful GLP-1 — particularly where its established cardiovascular outcome data (LEADER), pediatric labeling, or daily-titration profile is preferred. The newer once-weekly molecules have largely supplanted it for adult obesity, but it deserves its place in the incretin family as the molecule that brought the class into mainstream practice.